tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

Numerous studies have shown that even when imaging does not reveal the presence of cancer cells, traces of tumor DNA (i.e. originating from cancer cells) can be detected in the blood of certain patients: this is called molecular residual disease (MRD). When such traces are detected (we speak of MRD+ status), the risk of relapse is much higher than when there is no circulating tumor DNA (MRD - status). Given the success of immunotherapy in treating patients with metastatic disease in a variety of tumor types, there is enormous enthusiasm for expanding the use of immunotherapy to people with can

Trial Details

NCT ID
NCT06332274
Phase
PHASE3
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Tislelizumab
  • Blood sampling
  • Placebo
Locations (sample)
  • Villejuif, Val De Marne, France|48.7939,2.35992

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Completion of surgical and peri-operative treatments as per international guidelines.
  • Subject must have completed standard curative-intent therapy (i.e: Surgery, Neoadjuvant and adjuvant therapy) for minimum 3 months and maximum 4.5 …
  • Subject must not have standard treatment at least 3 weeks before blood sampling for ctDNA analyses.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →